Human Immunodeficiency Virus – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
MARKET OUTLOOK
The HIV therapy market is crowded with many approved antiretroviral (ARV) therapies. Growth in this market is being driven by increasing acceptance of new, high-priced ARVs, particularly the latest single-tablet regimens (STRs), which have enhanced side-effect profiles (e.g., improved safety and tolerability, lower pill burden). The introduction of single-pill nuc-sparing and nuc-reduced regimens (e.g., ViiV's Juluca and Dovato), which have a lower long-term risk of comorbidities, may expand treatment options and allow preferential prescribing to HIV patients who are compliant with their treatment regimens. In addition, the approval of ViiV's Cabenuva in 2021 has ushered in a new era of long-acting regimens that will help eliminate the requirement for lifelong daily pills. Finally, a large and aging predominantly viremic patient population whose requirements will shift to treatment of their comorbidities as their HIV infections are well managed will create new commercial opportunities. This claims data analysis offers insight into the current treatment landscape and physicians’ prescribing practices in HIV.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HIV patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HIV patients?
- How have Biktarvy, Dovato, Juluca, Symtuza, Cabenuva, and others been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of HIV patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HIV patients are treated with STRs versus multiple-tablet regimens? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States.
Key drugs: Biktarvy, Dovato, Juluca, Symtuza, Delstrigo, Rukobia, Trogarzo, Cabenuva, Truvada, Descovy.
Table of contents
- Human Immunodeficiency Virus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Human Immunodeficiency Virus US March 2022
- Treatment Algorithms CDA Human Immunodeficiency Virus US 2022 Dashboard
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.